ARCHIVES

Perjeta, Herceptin & Docetaxel Combination Extended Survival in HER2-Positive Disease

This article is from The Cancer Letter archive.

Vol. 35 No. 12 | December 28, 2012

Download PDF Visit The Full Archive

Related Articles

Preventive Surgery Cuts Risk Of Breast, Ovarian Cancers

May 31, 2002

White House Preparing To Nominate Andrew von Eschenbach as FDA Commissioner, Sources Said

March 3, 2006

Want To Know What Cancer Research Projects Are Going On? CRESPAC Can Describe More Than 5,000

January 2, 1976

ODACSupports Temodal For Treatment of Astrocytoma

January 22, 1999

RFP Suggestions For Immunodiagnosis Research Offered

October 22, 1976

Funding Opportunity: PanCAN Offering $4.1 Million in Research Grants

September 12, 2014